Dublin, Dec. 07, 2015 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/763qfd/nitric_oxide) has announced the addition of Jain PharmaBiotech's new report "Nitric Oxide - Therapeutics, Markets and Companies" to their offering.
This report Analyses the latest concepts of nitric oxide (NO) and the role it plays in health and disease as a basis for therapeutics and development of new drugs. Major segments of the market for nitric oxide-based drugs are described as well as the companies involved in developing them.
Various pharmacological approaches are described along with their therapeutic relevance. Various approaches are compared using SWOT (Strengths, Weaknesses, Opportunities, Threats) analysis. NO-based therapies are compared with conventional approaches and opportunities for combination with modern biotechnology approaches are described.
Share of drugs where NO is involved in the mechanism of action is analyzed in the worldwide pharmaceutical market for 2014 and is projected to 2019 and 2024 as new drugs with NO-based mechanisms are introduced into the market. Various strategies for developing such drugs are discussed.
Several companies have a product or products involving NO and free radicals. The report includes profiles of 34 companies involved in this area of which 8 have a significant interest in NO-based therapeutics. Other players are pharmaceutical and biotechnology companies as well as suppliers of products for NO research. Unfulfilled needs in the development of NO-based therapeutics are identified. Important 15 collaborations in this area are tabulated.
There are numerous publications relevant to NO. Selected 500 references are included in the bibliography. The text is supplemented with 25 tables and 26 figures.It is concluded that the future prospects for NO-based therapies are bright and fit in with biotechnology-based approaches to modern drug discovery and development. It is anticipated that some of these products will help in meeting the unfulfilled needs in human therapeutics.
Key Topics Covered:
Executive Summary
1. Introduction
2. Nitric Oxide Pathways
3. Role of NO in Physiology
4. Role of NO in Diseases
5. Pharmacology of Nitric Oxide
6. Therapeutic Applications
7. Evaluation of NO-Based Drugs
8. Markets for NO-based Therapies
9. Companies
10. References
For more information visit http://www.researchandmarkets.com/research/763qfd/nitric_oxide
Source: Jain PharmaBiotech
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices


SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 



